Indegene（544172）株式概要Indegene Limitedは、インド、米国、欧州、および国際的なライフサイエンス商業化企業として事業を展開している。 詳細544172 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長4/6過去の実績2/6財務の健全性6/6配当金3/6報酬株価収益率（ 29.3 x）は、 Life Sciences業界平均（ 41 x）を下回っています。収益は年間21.27%増加すると予測されています 同業他社や業界と比較して、良好な取引価格 アナリストらは、株価が23.9%上昇するだろうとほぼ一致している。 リスク分析リスクチェックの結果、544172 、リスクは検出されなかった。すべてのリスクチェックを見る544172 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW480,107 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA480,107 investors already sharing narrativesYour Fair Value₹Current Price₹488.553.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture071b2016201920222025202620282031Revenue ₹71.0bEarnings ₹8.1bAdvancedSet Fair ValueView all narrativesIndegene Limited 競合他社Akums Drugs and PharmaceuticalsSymbol: NSEI:AKUMSMarket cap: ₹106.5bSyngene InternationalSymbol: NSEI:SYNGENEMarket cap: ₹160.5bInnova CaptabSymbol: NSEI:INNOVACAPMarket cap: ₹55.4bSai Life SciencesSymbol: NSEI:SAILIFEMarket cap: ₹263.1b価格と性能株価の高値、安値、推移の概要Indegene過去の株価現在の株価₹488.5552週高値₹596.5052週安値₹414.90ベータ0.731ヶ月の変化-7.82%3ヶ月変化-0.51%1年変化-12.13%3年間の変化n/a5年間の変化n/aIPOからの変化-14.39%最新ニュースReported Earnings • Jul 19Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹16.72 (down from ₹17.15 in FY 2025). Revenue: ₹35.1b (up 24% from FY 2025). Net income: ₹4.01b (down 1.4% from FY 2025). Profit margin: 11% (down from 14% in FY 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.6%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.お知らせ • Jul 16+ 1 more updateIndegene Limited, Annual General Meeting, Aug 13, 2026Indegene Limited, Annual General Meeting, Aug 13, 2026, at 16:30 Indian Standard Time.お知らせ • Jul 10Indegene Limited to Report Q1, 2027 Results on Jul 30, 2026Indegene Limited announced that they will report Q1, 2027 results on Jul 30, 2026お知らせ • Apr 21Indegene Limited to Report Q4, 2026 Results on Apr 29, 2026Indegene Limited announced that they will report Q4, 2026 results on Apr 29, 2026Reported Earnings • Jan 30Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2026 results: EPS: ₹4.29 (down from ₹4.59 in 3Q 2025). Revenue: ₹9.42b (up 31% from 3Q 2025). Net income: ₹1.03b (down 6.2% from 3Q 2025). Profit margin: 11% (down from 15% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) missed analyst estimates by 8.1%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.お知らせ • Jan 22Indegene Limited to Report Q3, 2026 Results on Jan 29, 2026Indegene Limited announced that they will report Q3, 2026 results on Jan 29, 2026最新情報をもっと見るRecent updatesReported Earnings • Jul 19Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹16.72 (down from ₹17.15 in FY 2025). Revenue: ₹35.1b (up 24% from FY 2025). Net income: ₹4.01b (down 1.4% from FY 2025). Profit margin: 11% (down from 14% in FY 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.6%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.お知らせ • Jul 16+ 1 more updateIndegene Limited, Annual General Meeting, Aug 13, 2026Indegene Limited, Annual General Meeting, Aug 13, 2026, at 16:30 Indian Standard Time.お知らせ • Jul 10Indegene Limited to Report Q1, 2027 Results on Jul 30, 2026Indegene Limited announced that they will report Q1, 2027 results on Jul 30, 2026お知らせ • Apr 21Indegene Limited to Report Q4, 2026 Results on Apr 29, 2026Indegene Limited announced that they will report Q4, 2026 results on Apr 29, 2026Reported Earnings • Jan 30Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2026 results: EPS: ₹4.29 (down from ₹4.59 in 3Q 2025). Revenue: ₹9.42b (up 31% from 3Q 2025). Net income: ₹1.03b (down 6.2% from 3Q 2025). Profit margin: 11% (down from 15% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) missed analyst estimates by 8.1%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.お知らせ • Jan 22Indegene Limited to Report Q3, 2026 Results on Jan 29, 2026Indegene Limited announced that they will report Q3, 2026 results on Jan 29, 2026Buy Or Sell Opportunity • Nov 24Now 21% overvaluedOver the last 90 days, the stock has fallen 8.2% to ₹515. The fair value is estimated to be ₹426, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last year. Earnings per share has grown by 14%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 27% in the next 2 years.Reported Earnings • Nov 01Second quarter 2026 earnings released: EPS: ₹4.26 (vs ₹3.84 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.26 (up from ₹3.84 in 2Q 2025). Revenue: ₹8.24b (up 20% from 2Q 2025). Net income: ₹1.02b (up 11% from 2Q 2025). Profit margin: 12% (down from 13% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.お知らせ • Oct 23Indegene Limited to Report Q2, 2026 Results on Oct 30, 2025Indegene Limited announced that they will report Q2, 2026 results on Oct 30, 2025Board Change • Oct 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. Non-Executive Independent Director Georgia Papathomas was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Aug 03First quarter 2026 earnings released: EPS: ₹4.86 (vs ₹3.79 in 1Q 2025)First quarter 2026 results: EPS: ₹4.86 (up from ₹3.79 in 1Q 2025). Revenue: ₹7.61b (up 13% from 1Q 2025). Net income: ₹1.16b (up 33% from 1Q 2025). Profit margin: 15% (up from 13% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.お知らせ • Jul 24Indegene Limited to Report Q1, 2026 Results on Jul 31, 2025Indegene Limited announced that they will report Q1, 2026 results on Jul 31, 2025お知らせ • Jun 06An undisclosed buyer agreed to acquire an unknown minority stake in Indegene Limited (NSEI:INDGN) from CA Dawn Investments.An undisclosed buyer agreed to acquire 10.19% stake in Indegene Limited (NSEI:INDGN) from CA Dawn Investments on June 3, 2025. The expected date of completion is June 06, 2025.Reported Earnings • Jun 01Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹17.15 (up from ₹15.19 in FY 2024). Revenue: ₹28.4b (up 9.6% from FY 2024). Net income: ₹4.07b (up 21% from FY 2024). Profit margin: 14% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.お知らせ • May 29Indegene Limited, Annual General Meeting, Jun 26, 2025Indegene Limited, Annual General Meeting, Jun 26, 2025, at 16:30 Indian Standard Time.Reported Earnings • May 02Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹17.15 (up from ₹15.19 in FY 2024). Revenue: ₹28.4b (up 9.6% from FY 2024). Net income: ₹4.07b (up 21% from FY 2024). Profit margin: 14% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India.New Risk • Apr 30New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 0.4% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.お知らせ • Apr 21Indegene Limited to Report Q4, 2025 Results on Apr 28, 2025Indegene Limited announced that they will report Q4, 2025 results on Apr 28, 2025お知らせ • Feb 25Indegene Launches Cortex, A Fit-For-Purpose Generative Ai PlatformIndegene Launches Cortex, A Fit-For-Purpose Generative AI Platform, Verticalized For The Life Sciences Industry Bengaluru, India and Princeton, US, February 24, 2025: Indegene, a digital-first, life sciences commercialization company, launched Cortex, a fit-for-purpose Generative AI (GenAI) platform, verticalized for the life sciences industry. As a life sciences-specialist knowledge engineering and multi- agent orchestration platform, Cortex by Indegene enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance. This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain, making medical writing more effective and efficient, and accelerating Medical-Legal-Regulatory (MLR) reviews. Its knowledge engineering interface codifies Indegene's 25+ years of subject matter expertise into advanced knowledge graphs using a domain-friendly interface. Moreover, its fit-for-purpose agents can be configured with any preferred Large Language Model (LLM) and evolve as LLM improves. Further, its multi-agent orchestration enables use case-specific applications for enterprise-wide system integration. Together, these yield more reliable, accurate and trustworthy outcomes from LLM-based agents with substantially faster turnaround times and better ROI at lower risk, relative to industry-agnostic platforms. This GenAI platform's embedded domain knowledge graphs capture nuances and details of life sciences' processes and tasks and benefit from continuous improvement.Reported Earnings • Jan 31Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: EPS: ₹4.59 (up from ₹4.45 in 3Q 2024). Revenue: ₹7.58b (up 10% from 3Q 2024). Net income: ₹1.10b (up 11% from 3Q 2024). Profit margin: 14% (in line with 3Q 2024). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) also surpassed analyst estimates by 2.2%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.Recent Insider Transactions • Dec 29Chairman & CEO recently bought ₹10m worth of stockOn the 24th of December, Manish Gupta bought around 17k shares on-market at roughly ₹599 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹60m. This was Manish's only on-market trade for the last 12 months.Recent Insider Transactions • Dec 20Non-Executive Director recently bought ₹60m worth of stockOn the 17th of December, Rajesh Nair bought around 100k shares on-market at roughly ₹596 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹14m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Dec 07Insider recently sold ₹13m worth of stockOn the 5th of December, Viveksheel Ghai sold around 20k shares on-market at roughly ₹628 per share. This transaction amounted to 3.7% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹33m. Insiders have been net sellers, collectively disposing of ₹46m more than they bought in the last 12 months.Reported Earnings • Oct 29Second quarter 2025 earnings releasedSecond quarter 2025 results: EPS: ₹3.84. Net income: ₹917.0m (up ₹917.0m from 2Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India.お知らせ • Oct 23Indegene Limited to Report Q2, 2025 Results on Oct 28, 2024Indegene Limited announced that they will report Q2, 2025 results on Oct 28, 2024Recent Insider Transactions • Oct 01Chief Financial Officer recently sold ₹33m worth of stockOn the 27th of September, Suhas Prabhu sold around 50k shares on-market at roughly ₹669 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Suhas' only on-market trade for the last 12 months.Valuation Update With 7 Day Price Move • Sep 10Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹675, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 46x in the Life Sciences industry in India. Simply Wall St's valuation model estimates the intrinsic value at ₹273 per share.お知らせ • Aug 07Indegene Limited, Annual General Meeting, Sep 06, 2024Indegene Limited, Annual General Meeting, Sep 06, 2024, at 16:30 Indian Standard Time.Reported Earnings • Aug 02First quarter 2025 earnings released: EPS: ₹3.79 (vs ₹3.09 in 1Q 2024)First quarter 2025 results: EPS: ₹3.79 (up from ₹3.09 in 1Q 2024). Revenue: ₹6.99b (up 9.9% from 1Q 2024). Net income: ₹877.0m (up 28% from 1Q 2024). Profit margin: 13% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Life Sciences industry in Asia.お知らせ • Jul 25Indegene Limited to Report Q1, 2025 Results on Aug 01, 2024Indegene Limited announced that they will report Q1, 2025 results on Aug 01, 2024お知らせ • May 23Indegene Limited to Report Q4, 2024 Results on May 29, 2024Indegene Limited announced that they will report Q4, 2024 results on May 29, 2024株主還元544172IN Life SciencesIN 市場7D-4.5%0.8%-0.4%1Y-12.1%4.7%-1.2%株主還元を見る業界別リターン: 544172過去 1 年間で4.7 % の収益を上げたIndian Life Sciences業界を下回りました。リターン対市場: 544172は、過去 1 年間で-1.2 % のリターンを上げたIndian市場を下回りました。価格変動Is 544172's price volatile compared to industry and market?544172 volatility544172 Average Weekly Movement3.6%Life Sciences Industry Average Movement5.3%Market Average Movement6.0%10% most volatile stocks in IN Market9.1%10% least volatile stocks in IN Market3.8%安定した株価: 544172 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 544172の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19984,687Manish Guptawww.indegene.comIndegene Limitedは、インド、米国、欧州、および国際的なライフサイエンス商業化企業として事業を展開している。事業セグメントは3つ：Enterprise Medical Solutions、Enterprise Commercial Solutions、Omnichannel Activation & Others。同社はバイオ医薬品、新興バイオテクノロジー、医療機器企業向けにバイオテクノロジーや医療機器を開発している。また、企業向け商業・医療・臨床ソリューション、オムニチャネル活性化ソリューションも提供している。さらに、NEXTテクノロジープラットフォームも運営している。さらに、分析、技術、商業、医療、規制、安全サービスをライフサイエンスおよびヘルスケア企業に提供している。Indegene Limitedは1998年に設立され、インドのベンガルールを拠点としている。もっと見るIndegene Limited 基礎のまとめIndegene の収益と売上を時価総額と比較するとどうか。544172 基礎統計学時価総額₹117.68b収益（TTM）₹4.01b売上高(TTM)₹35.11b29.3xPER（株価収益率3.4xP/Sレシオ544172 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計544172 損益計算書（TTM）収益₹35.11b売上原価₹778.00m売上総利益₹34.33bその他の費用₹30.32b収益₹4.01b直近の収益報告Mar 31, 2026次回決算日Jul 30, 2026一株当たり利益（EPS）16.65グロス・マージン97.78%純利益率11.43%有利子負債／自己資本比率0.4%544172 の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.5%現在の配当利回り13%配当性向544172 配当は確実ですか？544172 配当履歴とベンチマークを見る544172 、いつまでに購入すれば配当金を受け取れますか？Indegene 配当日配当落ち日Jul 31 2026配当支払日Sep 12 2026配当落ちまでの日数7 days配当支払日までの日数50 days544172 配当は確実ですか？544172 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 02:42終値2026/07/23 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Indegene Limited 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関null null360 ONE Capital Market Private LimitedDeep Shah360 ONE Capital Market Private LimitedRajiv BerliaCitigroup Inc11 その他のアナリストを表示
Reported Earnings • Jul 19Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹16.72 (down from ₹17.15 in FY 2025). Revenue: ₹35.1b (up 24% from FY 2025). Net income: ₹4.01b (down 1.4% from FY 2025). Profit margin: 11% (down from 14% in FY 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.6%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.
お知らせ • Jul 16+ 1 more updateIndegene Limited, Annual General Meeting, Aug 13, 2026Indegene Limited, Annual General Meeting, Aug 13, 2026, at 16:30 Indian Standard Time.
お知らせ • Jul 10Indegene Limited to Report Q1, 2027 Results on Jul 30, 2026Indegene Limited announced that they will report Q1, 2027 results on Jul 30, 2026
お知らせ • Apr 21Indegene Limited to Report Q4, 2026 Results on Apr 29, 2026Indegene Limited announced that they will report Q4, 2026 results on Apr 29, 2026
Reported Earnings • Jan 30Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2026 results: EPS: ₹4.29 (down from ₹4.59 in 3Q 2025). Revenue: ₹9.42b (up 31% from 3Q 2025). Net income: ₹1.03b (down 6.2% from 3Q 2025). Profit margin: 11% (down from 15% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) missed analyst estimates by 8.1%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.
お知らせ • Jan 22Indegene Limited to Report Q3, 2026 Results on Jan 29, 2026Indegene Limited announced that they will report Q3, 2026 results on Jan 29, 2026
Reported Earnings • Jul 19Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹16.72 (down from ₹17.15 in FY 2025). Revenue: ₹35.1b (up 24% from FY 2025). Net income: ₹4.01b (down 1.4% from FY 2025). Profit margin: 11% (down from 14% in FY 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.6%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.
お知らせ • Jul 16+ 1 more updateIndegene Limited, Annual General Meeting, Aug 13, 2026Indegene Limited, Annual General Meeting, Aug 13, 2026, at 16:30 Indian Standard Time.
お知らせ • Jul 10Indegene Limited to Report Q1, 2027 Results on Jul 30, 2026Indegene Limited announced that they will report Q1, 2027 results on Jul 30, 2026
お知らせ • Apr 21Indegene Limited to Report Q4, 2026 Results on Apr 29, 2026Indegene Limited announced that they will report Q4, 2026 results on Apr 29, 2026
Reported Earnings • Jan 30Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2026 results: EPS: ₹4.29 (down from ₹4.59 in 3Q 2025). Revenue: ₹9.42b (up 31% from 3Q 2025). Net income: ₹1.03b (down 6.2% from 3Q 2025). Profit margin: 11% (down from 15% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) missed analyst estimates by 8.1%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.
お知らせ • Jan 22Indegene Limited to Report Q3, 2026 Results on Jan 29, 2026Indegene Limited announced that they will report Q3, 2026 results on Jan 29, 2026
Buy Or Sell Opportunity • Nov 24Now 21% overvaluedOver the last 90 days, the stock has fallen 8.2% to ₹515. The fair value is estimated to be ₹426, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last year. Earnings per share has grown by 14%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 27% in the next 2 years.
Reported Earnings • Nov 01Second quarter 2026 earnings released: EPS: ₹4.26 (vs ₹3.84 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.26 (up from ₹3.84 in 2Q 2025). Revenue: ₹8.24b (up 20% from 2Q 2025). Net income: ₹1.02b (up 11% from 2Q 2025). Profit margin: 12% (down from 13% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.
お知らせ • Oct 23Indegene Limited to Report Q2, 2026 Results on Oct 30, 2025Indegene Limited announced that they will report Q2, 2026 results on Oct 30, 2025
Board Change • Oct 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. Non-Executive Independent Director Georgia Papathomas was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Aug 03First quarter 2026 earnings released: EPS: ₹4.86 (vs ₹3.79 in 1Q 2025)First quarter 2026 results: EPS: ₹4.86 (up from ₹3.79 in 1Q 2025). Revenue: ₹7.61b (up 13% from 1Q 2025). Net income: ₹1.16b (up 33% from 1Q 2025). Profit margin: 15% (up from 13% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.
お知らせ • Jul 24Indegene Limited to Report Q1, 2026 Results on Jul 31, 2025Indegene Limited announced that they will report Q1, 2026 results on Jul 31, 2025
お知らせ • Jun 06An undisclosed buyer agreed to acquire an unknown minority stake in Indegene Limited (NSEI:INDGN) from CA Dawn Investments.An undisclosed buyer agreed to acquire 10.19% stake in Indegene Limited (NSEI:INDGN) from CA Dawn Investments on June 3, 2025. The expected date of completion is June 06, 2025.
Reported Earnings • Jun 01Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹17.15 (up from ₹15.19 in FY 2024). Revenue: ₹28.4b (up 9.6% from FY 2024). Net income: ₹4.07b (up 21% from FY 2024). Profit margin: 14% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.
お知らせ • May 29Indegene Limited, Annual General Meeting, Jun 26, 2025Indegene Limited, Annual General Meeting, Jun 26, 2025, at 16:30 Indian Standard Time.
Reported Earnings • May 02Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹17.15 (up from ₹15.19 in FY 2024). Revenue: ₹28.4b (up 9.6% from FY 2024). Net income: ₹4.07b (up 21% from FY 2024). Profit margin: 14% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India.
New Risk • Apr 30New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 0.4% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
お知らせ • Apr 21Indegene Limited to Report Q4, 2025 Results on Apr 28, 2025Indegene Limited announced that they will report Q4, 2025 results on Apr 28, 2025
お知らせ • Feb 25Indegene Launches Cortex, A Fit-For-Purpose Generative Ai PlatformIndegene Launches Cortex, A Fit-For-Purpose Generative AI Platform, Verticalized For The Life Sciences Industry Bengaluru, India and Princeton, US, February 24, 2025: Indegene, a digital-first, life sciences commercialization company, launched Cortex, a fit-for-purpose Generative AI (GenAI) platform, verticalized for the life sciences industry. As a life sciences-specialist knowledge engineering and multi- agent orchestration platform, Cortex by Indegene enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance. This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain, making medical writing more effective and efficient, and accelerating Medical-Legal-Regulatory (MLR) reviews. Its knowledge engineering interface codifies Indegene's 25+ years of subject matter expertise into advanced knowledge graphs using a domain-friendly interface. Moreover, its fit-for-purpose agents can be configured with any preferred Large Language Model (LLM) and evolve as LLM improves. Further, its multi-agent orchestration enables use case-specific applications for enterprise-wide system integration. Together, these yield more reliable, accurate and trustworthy outcomes from LLM-based agents with substantially faster turnaround times and better ROI at lower risk, relative to industry-agnostic platforms. This GenAI platform's embedded domain knowledge graphs capture nuances and details of life sciences' processes and tasks and benefit from continuous improvement.
Reported Earnings • Jan 31Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: EPS: ₹4.59 (up from ₹4.45 in 3Q 2024). Revenue: ₹7.58b (up 10% from 3Q 2024). Net income: ₹1.10b (up 11% from 3Q 2024). Profit margin: 14% (in line with 3Q 2024). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) also surpassed analyst estimates by 2.2%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.
Recent Insider Transactions • Dec 29Chairman & CEO recently bought ₹10m worth of stockOn the 24th of December, Manish Gupta bought around 17k shares on-market at roughly ₹599 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹60m. This was Manish's only on-market trade for the last 12 months.
Recent Insider Transactions • Dec 20Non-Executive Director recently bought ₹60m worth of stockOn the 17th of December, Rajesh Nair bought around 100k shares on-market at roughly ₹596 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹14m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Dec 07Insider recently sold ₹13m worth of stockOn the 5th of December, Viveksheel Ghai sold around 20k shares on-market at roughly ₹628 per share. This transaction amounted to 3.7% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹33m. Insiders have been net sellers, collectively disposing of ₹46m more than they bought in the last 12 months.
Reported Earnings • Oct 29Second quarter 2025 earnings releasedSecond quarter 2025 results: EPS: ₹3.84. Net income: ₹917.0m (up ₹917.0m from 2Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India.
お知らせ • Oct 23Indegene Limited to Report Q2, 2025 Results on Oct 28, 2024Indegene Limited announced that they will report Q2, 2025 results on Oct 28, 2024
Recent Insider Transactions • Oct 01Chief Financial Officer recently sold ₹33m worth of stockOn the 27th of September, Suhas Prabhu sold around 50k shares on-market at roughly ₹669 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Suhas' only on-market trade for the last 12 months.
Valuation Update With 7 Day Price Move • Sep 10Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹675, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 46x in the Life Sciences industry in India. Simply Wall St's valuation model estimates the intrinsic value at ₹273 per share.
お知らせ • Aug 07Indegene Limited, Annual General Meeting, Sep 06, 2024Indegene Limited, Annual General Meeting, Sep 06, 2024, at 16:30 Indian Standard Time.
Reported Earnings • Aug 02First quarter 2025 earnings released: EPS: ₹3.79 (vs ₹3.09 in 1Q 2024)First quarter 2025 results: EPS: ₹3.79 (up from ₹3.09 in 1Q 2024). Revenue: ₹6.99b (up 9.9% from 1Q 2024). Net income: ₹877.0m (up 28% from 1Q 2024). Profit margin: 13% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Life Sciences industry in Asia.
お知らせ • Jul 25Indegene Limited to Report Q1, 2025 Results on Aug 01, 2024Indegene Limited announced that they will report Q1, 2025 results on Aug 01, 2024
お知らせ • May 23Indegene Limited to Report Q4, 2024 Results on May 29, 2024Indegene Limited announced that they will report Q4, 2024 results on May 29, 2024
